| |
>> How in the world do you KNOW he is doing "estate planning?"
We don't. It's just a theory. You're correct in suggesting such speculation has no place on this thread, however.
Frankly, I'm getting a little tired of all of the speculation going on here too. Visit the TRIBY thread and you'll see a good example of too many people saying too much about too little. There are good posts once in a while, but you have to wade through dozens of posts from nervous-nelly investors commenting on every tick and block sale. Heck, they even talk about the weather.. Let's not let that happen here, please.
As for the current stock price, all I can say is that I've been an investor for over two years and have seen it go as low as 7/8 (bought a bunch then) and as high as 6-something a few months later (sold some around 5 on the way up). This stock can really move on news, and no news usually results in a slow sell off. This last week, we've been seeing a pick up in volume and a slow downward trend. I don't know what this means, if anything.
The only thing we have to ask ourselves is, do we believe management is doing the right things to position themselves in this very-new quick diagnostics market? Personlly, I'm big on this market in general and hold QDEL, TRIBY, and CMTR. I think QDEL is the strongest of the three and most likely to do well in the short term. CMTR and TRIBY are more speculative, but have to most to gain from relatively small increases in sales.
Assuming the Merck deal and HIV approval are still on track, then I can't think of any reason not to buy more at these prices.
Call me "excessively optimistic," but that's my honest opinion. |
|
